Telix Pharmaceuticals (ASX:TLX) has announced that preliminary results from the Phase 2 IPAX-Linz study of TLX101 in recurrent high-grade glioma support the patient benefit seen in the IPAX-1 study. …
Telix says IPAX-Linz study shows promising efficacy for glioma therapy candidate
April 16, 2025 Australian Biotech
Latest Video
New Stories
-
Medicines Australia announces appointment of communications director
April 28, 2025 - - Latest News -
New survey confirms significant interest in accessing weight loss therapies
April 28, 2025 - - Latest News -
Recce Pharmaceuticals enters research and development agreement with US defence
April 28, 2025 - - Australian Biotech -
Radiopharm Theranostics doses first patient in US Phase 2b imaging study of brain metastasis
April 28, 2025 - - Australian Biotech -
Dimerix says FDA confirms proteinuria as acceptable endpoint for DMX-200 Phase 3 trial
April 28, 2025 - - Australian Biotech -
Stakeholders welcome the PBS listing of AbbVie's blood cancer therapy
April 28, 2025 - - Latest News -
Repurposed diabetes drug could deliver gains for people living with major joint pain
April 27, 2025 - - Latest News